Information Provided By: 
Fly News Breaks for June 15, 2016
EXAS
Jun 15, 2016 | 15:16 EDT
Jefferies analyst Brandon Couillard views the updated USPSTF guidelines as a significant positive for Exact Sciences that eliminates many of the overhangs on the company's commercial story and seemingly opens up the possibility for mandated commercial payor coverage of its Cologuard test. The analyst noted that prior to the initial USPSTF draft report late last year, Exact Sciences' shares traded in the $18-$20 per share range. Couillard keeps a Buy rating and $13 price target on the stock.
News For EXAS From the Last 2 Days
There are no results for your query EXAS
